<- Go Home
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Market Cap
$34.2M
Volume
173.6K
Cash and Equivalents
$2.8M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$5.94
52 Week Low
$1.50
Dividend
N/A
Price / Book Value
11.29
Price / Earnings
-1.91
Price / Tangible Book Value
11.29
Enterprise Value
$31.6M
Enterprise Value / EBITDA
-1.89
Operating Income
-$16.7M
Return on Equity
173.99%
Return on Assets
-94.96
Cash and Short Term Investments
$2.8M
Debt
$145.0K
Equity
$2.8M
Revenue
N/A
Unlevered FCF
-$6.2M
Sector
Biotechnology
Category
N/A